Table 4.
Fitted multivariate Bayesian lognormal survival regression model assessing effects of treatment arms and covariates on post-transplant overall survival (N=70, Deaths=35). Dose arm effects are compared to baseline arm Flu 30 mg/m2 + Clo 10 mg/m2. All doses are mg/m2/day.
| Posterior Quantities | |||
|---|---|---|---|
|
| |||
| Variable | Mean Effect (SD) | Posterior 95% Credible Interval | Probability of a Beneficial Effect* |
| Intercept | 9.23 (2.29) | 4.91, 13.92 | -- |
| Flu 20 + Clo 20 | -1.90 (1.08) | -4.12, 0.16 | 0.04 |
| Flu 10 + Clo 30 | -0.21 (0.77) | -1.78, 1.27 | 0.39 |
| Flu 0 + Clo 40 | 1.15 (0.94) | -0.67, 3.01 | 0.90 |
| Age at SCT | -0.22 (0.60) | -1.41, 0.95 | 0.36 |
| MUD donor type | 0.44 (0.64) | -0.82, 1.73 | 0.76 |
| In CR at SCT | -0.28 (0.79) | -1.83, 1.31 | 0.36 |
| AML/MDS disease | -1.67 (0.89) | -3.52, 0.02 | 0.03 |
Abbreviations: Flu = fludarabine, Clo= clofarabine; SCT = stem cell transplantation; MUD = matched unrelated donor; CR, = complete remission; SD = standard deviation.
*
This is the Probability of a Beneficial Effect, not the P value.